Author:
Tokuchi Yoshimasa,Suda Goki,Kimura Megumi,Maehara Osamu,Kitagataya Takashi,Kubo Akinori,Yoshida Sonoe,Fu Qingjie,Yang Zijian,Hosoda Shunichi,Ohara Masatsugu,Yamada Ren,Suzuki Kazuharu,Kawagishi Naoki,Nakai Masato,Sho Takuya,Natsuizaka Mitsuteru,Morikawa Kenichi,Ogawa Koji,Ohnishi Shunsuke,Sakamoto Naoya
Abstract
AbstractWe aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and ≥ 12 months were included. Altogether, 70.7% of patients (41/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (r = 0305, P = 0.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels. l-carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA.
Funder
Japan Agency for Medical Research and Development
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献